Israeli Researchers develop a game-changing bio-sensing technology for predicting cancer treatment response


June 5, 2023:  A team of researchers from Ben-Gurion University of the Negev (BGU) has developed a groundbreaking bio-sensing technology that predicts the response of cancer patients to anti-PD1, an immune checkpoint inhibitor (ICI) therapy, with significantly greater accuracy than current methods.

The study’s results were published late last week in the prestigious journal Science Advances.

The study was led by Bar Kaufman, a talented MD-Ph.D. student, and Master’s student Orli Abramov, under the guidance of Prof. Moshe Elkabets and Prof. Angel Porgador from the Faculty of Health Sciences at BGU, along with collaborators from Soroka Medical Center and Barzilai Hospital.

ALSO READ: Chitkara University Among Top 100 in Various Categories in NIRF Rankings

This bio-sensing technology, called the Immune-checkpoint Artificial Reporter with overexpression of PD1 (IcAR-PD1), measures the binding functionality of PD1 ligands, PDL1 and PDL2, to their receptor PD1. The researchers found that assessing the functionality of PD1 ligands was an effective predictor to identify who will positively respond to anti-PD1 and will benefit from this treatment. The anti-PD1 is the leading immunotherapy (ICI) treatment in cancer patients, thus such achievement can impact the quality of life of thousands of cancer patients worldwide every day.

The IcAR technology is a groundbreaking development that enables the measurement of the functionality, in principle, of any immuno-modulator targets in medical oncology. What that means is that doctors can now use the IcAR-PD1 technology to predict which patients will respond best to anti-PD1 therapies and tailor treatments accordingly, while sparing non-responders from ineffective treatment. In the future, this bioassay technology may help predict responses to other ICI therapies and could be used to tailor personalized ICI treatment protocols. The major Researchers advances of the IcAR technology are the accuracy and sensitivity along with its logistical simplicity. The technology enables the screening of substantial amounts of cancer samples without requiring fresh biopsies or biological material, making it accessible for medical care in Israel and abroad. By solving the logistical bottleneck, the researchers make the diagnostic tool easier for doctors to identify potential responders.

Prof. Porgador emphasized that this diagnostic test does not require additional biopsy as it is based on the fixed tumor tissue available for cancer patients directly from the pathology unit of their medical center.

Online Courses with Certification

“In summary, IcAR technology is expected to be a game-changer in the world of cancer treatment diagnostics,” declared Prof. Elkabets, “It will enable accurate prediction of patient response to ICI therapies, and it has the potential to improve the lives of cancer patients by identifying effective treatment options in a personalized manner.”

This research was made possible thanks to support from the Israel Cancer Research Fund (ICRF) accelerator program and the Israel Science Foundation for Prof. Moshe Elkabets and Prof. Angel Porgador.

About Ben-Gurion University of the Negev

Ben-Gurion University of the Negev embraces the endless potential we have as individuals and as a commonality to adapt and to thrive in changing environments. Inspired by our location in the desert, we aim to discover, to create, and to develop solutions to dynamic challenges, to pose questions that have yet to be asked, and to push beyond the boundaries of the commonly accepted and possible.  

We are proud to be a central force for inclusion, diversity and innovation in Israel, and we strive to extend the Negev’s potential and our entrepreneurial spirit throughout the world. For example, the multi-disciplinary School for Sustainability and Climate Change at BGU leverages over 50 years of expertise on living and thriving in the desert into scalable solutions for people everywhere. 

At a glance

20,000 students | 800 senior faculty | 3 campuses | 6 faculties: humanities & social sciences, health sciences, engineering sciences, natural sciences, business & management, and desert research. 

We invite you to set aside existing paradigms and to view the world from our unconventional perspective.

This year educate yourself and develop your career with EasyShiksha